Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Erythropoiesis Stimulating Agent (ESA) Use for Anemic Cancer and Chronic Kidney Disease (CKD) Patients in 2008: Advocacy for Conservative Use

Charles L. Bennett, MD, PhD, MPP, Benjamin Kim, MD, Athena T Samaras, BA, Allen R Nissenson, MD, FACP, A. Oliver Sartor, MD, D. Mark Courtney, MD, Robert I. Liem, MD, Dennis P West, PhD, Simone N Boyle, BA, Robin L Wagner, Carolyn E Goldstein, Steven M Trifilio, RPh, David M Spiegel, MD, FACP, Stephen Y Lai, MD, PhD

Blood (2008) 112 (11): 4680.

https://doi.org/10.1182/blood.V112.11.4680.4680

Published: 2008

Journal Articles

Evaluating Mortality with Erythropoietin Stimulating Agents (ESAs) in the Oncology Setting: The Importance of Selecting Trials That Include Survival or Loco-Regional Tumor Control as a Primary Endpoint

Athena T Samaras, BA, Sara E Barnato, MD, Benjamin Kim, MD, Stephen Y Lai, MD, PhD, A. Oliver Sartor, MD, June McKoy, MD, JD, MPH, Brian C Sauer, PhD, Charles L. Bennett, MD, PhD, MPP

Blood (2008) 112 (11): 4681.

https://doi.org/10.1182/blood.V112.11.4681.4681

Published: 2008

Journal Articles

Evaluation of Conflicts of Interest in Basic Science Studies Evaluating Erythropoietin and Erythropoietin Effects of Solid Cancer Cell Lines

Sara E Barnato, MD, Simone N Boyle, BA, Adam Kuykendal, MD, Stephen Y Lai, MD, PhD, Robin L Wagner, Carolyn E Goldstein, Athena T Samaras, BA, Dennis P West, PhD, Jacob Tallman, Michael Henke, MD, A. Oliver Sartor, MD, Charles L. Bennett, MD, PhD, MPP

Blood (2008) 112 (11): 672.

https://doi.org/10.1182/blood.V112.11.672.672

Published: 2008

Journal Articles

Genetic Evidence for an Additional Factor Required for Erythropoietin-Induced Signal Transduction

Sarah L. Gaffen, Stephen Y. Lai, Gregory D. Longmore, Kathleen D. Liu, Mark A. Goldsmith

Blood (1999) 94 (1): 74–86.

https://doi.org/10.1182/blood.V94.1.74.413k36_74_86

Published: 1999

Journal Articles

Redundant and Selective Roles for Erythropoietin Receptor Tyrosines in Erythropoiesis In Vivo

Gregory D. Longmore, Yun You, Jaime Molden, Kathleen D. Liu, Aki Mikami, Stephen Y. Lai, Pamela Pharr, Mark A. Goldsmith

Blood (1998) 91 (3): 870–878.

https://doi.org/10.1182/blood.V91.3.870

Published: 1998

NARROW

Erythropoiesis Stimulating Agent (ESA) Use for Anemic Cancer and Chronic Kidney Disease (CKD) Patients in 2008: Advocacy for Conservative Use

Evaluating Mortality with Erythropoietin Stimulating Agents (ESAs) in the Oncology Setting: The Importance of Selecting Trials That Include Survival or Loco-Regional Tumor Control as a Primary Endpoint

Evaluation of Conflicts of Interest in Basic Science Studies Evaluating Erythropoietin and Erythropoietin Effects of Solid Cancer Cell Lines

Genetic Evidence for an Additional Factor Required for Erythropoietin-Induced Signal Transduction

Redundant and Selective Roles for Erythropoietin Receptor Tyrosines in Erythropoiesis In Vivo

Email alerts

ASH Publications

American Society of Hematology

Erythropoiesis Stimulating Agent (ESA) Use for Anemic Cancer and Chronic Kidney Disease (CKD) Patients in 2008: Advocacy for Conservative Use

Evaluating Mortality with Erythropoietin Stimulating Agents (ESAs) in the Oncology Setting: The Importance of Selecting Trials That Include Survival or Loco-Regional Tumor Control as a Primary Endpoint

Evaluation of Conflicts of Interest in Basic Science Studies Evaluating Erythropoietin and Erythropoietin Effects of Solid Cancer Cell Lines

Genetic Evidence for an Additional Factor Required for Erythropoietin-Induced Signal Transduction

Redundant and Selective Roles for Erythropoietin Receptor Tyrosines in Erythropoiesis In Vivo

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only